Transparency Market Research Report Added "Epilepsy Therapeutics Market" to its database.

Albany, NY -- (SBWire) -- 04/12/2016 --A new market research report by Transparency Market Research, titled "Epilepsy Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019," offers a comprehensive overview of the global epilepsy therapeutics market. The report points out the key factors affecting the growth of the market and estimates the growth and valuation of the market till the end of 2019. The impact of Porter's five forces on the growth of the market has been also analyzed. The report studies the overall market in terms of antiepileptic medicines and regions. Profiles of some of the key market players have also been included in the report.

Epilepsy refers to a group of long-term neurological disorders that is characterized by recurring seizures. These episodes of seizures occur when a group of nerve cells or neurons send wrong signals. Seizures differ from primary generalized seizures to partial seizures according to the cause of epilepsy. It has been observed that patients suffering from epilepsy complain about strange emotions and sensations and behave strangely during epileptic attacks. In children aged between 2-18 years, Dravet syndrome causes severe epileptic seizures that affect motor skills, language, and others.

For treating epilepsy, doctors prescribe antiepileptic medicines (AEDs) on the basis of the age of patient, type of seizures, severity of seizures, and the part of the brain involved. In terms of available AEDs, the report segments the global epilepsy therapeutics market into first- and second-generation AEDs. The first generation of AEDs includes valproate, carbamazepine, phenytoin, oxycarbazepine, phenobarbital, ethosuximide, primidone, and topiramate. Second-generation AEDs work through a different mechanism of action than the first generation. Second-generation AEDs include lamotrigine, pregabalin, levetiracetam, zonisamide, eslicarbazepine acetate, lacosamide, perampanel, ezogabine/retigabine, and rufinamide. Among first-generation AEDs, valproate, carbamazepine, phenytoin and oxycarbazepine dominate the overall market. However, during the forecast period, second-generation AEDs such as levetiracetam, zonisamide and lacosamide are expected to slowly take over the global epilepsy therapeutics market owing to their improved efficacy and tolerability.

Download PDF: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2448

The report studies the global epilepsy therapeutics market across North America, Asia Pacific, Europe, and Rest of the World. North America has been the leading region in the market, closely followed by Europe. The rapid growth of the market in North America can be attributed to the approval of three new AEDs in the U.S. since 2012. During the forecast horizon, Asia Pacific is anticipated to witness positive growth owing to the growing prevalence of epilepsy in India and China.

Some of the prominent players in the global epilepsy therapeutics market are GlaxoSmithKline plc, Abbott Laboratories, Cephalon Inc., Pfizer Inc., Johnson & Johnson, Novartis AG, Valeant Pharmaceuticals International Inc., Sunovion Pharmaceuticals Inc., Sanofi S.A., and Shire. 

Contact us:
Mr. Sudip S
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/